Clinical Trials
2 trialsNCT07504588 2026-06-03
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07178730 2026-05-06
ADAPT-TN-IV
West German Study Group
Phase 3 Not yet recruiting